Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real‐Life SettingMariele Gatto, Roberto Gerli, Marta Mosca et al.|Arthritis & Rheumatology|2020Cited by 113
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide studyLuca Iaccarino, Andrea Doria, Laura Andréoli et al.|Journal of Autoimmunity|2017Cited by 102
High Prevalence of Antinuclear Antibodies in Children with Thyroid AutoimmunityMaria Segni, Fabrizio Conti|Journal of Immunology Research|2014Cited by 27
IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cellsAlessio Ugolini, Marianna Nuti, Ilaria Grazia Zizzari et al.|EBioMedicine|2020Cited by 17
Belimumab Decreases Autophagy and Citrullination in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus ErythematosusTania Colasanti, Fabrizio Conti|Cells|2022Cited by 10